Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

A New Age-Structured Multiscale Model of the Hepatitis C Virus Life-Cycle During Infection and Therapy With Direct-Acting Antiviral Agents.

Quintela BM, Conway JM, Hyman JM, Guedj J, Dos Santos RW, Lobosco M, Perelson AS.

Front Microbiol. 2018 Apr 4;9:601. doi: 10.3389/fmicb.2018.00601. eCollection 2018.

2.

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.

Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, Gunther S, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X.

PLoS Med. 2018 Mar 27;15(3):e1002535. doi: 10.1371/journal.pmed.1002535. eCollection 2018 Mar.

3.

Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.

Fourati S, Guedj J, Chevaliez S, Nguyen THT, Roudot-Thoraval F, Ruiz I, Soulier A, Scoazec G, Varaut A, Poiteau L, Francois M, Mallat A, Hézode C, Pawlotsky JM.

Aliment Pharmacol Ther. 2018 Mar;47(5):665-673. doi: 10.1111/apt.14478. Epub 2017 Dec 22.

PMID:
29271114
4.

Erratum for Madelain et al., "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses".

Madelain V, Guedj J, Mentré F, Nguyen THT, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02093-17. doi: 10.1128/AAC.02093-17. Print 2018 Jan. No abstract available.

5.

Total Mesenteric Peritonectomy for Peritoneal Metastases (with video).

Cazauran JB, Lasseur A, Pasquer A, Rousset P, Guedj J, Passot G, Glehen O.

Ann Surg Oncol. 2017 Dec;24(13):3988-3989. doi: 10.1245/s10434-017-6099-5. Epub 2017 Oct 6.

PMID:
28986751
6.

Determining Ribavirin's mechanism of action against Lassa virus infection.

Carrillo-Bustamante P, Nguyen THT, Oestereich L, Günther S, Guedj J, Graw F.

Sci Rep. 2017 Sep 15;7(1):11693. doi: 10.1038/s41598-017-10198-0.

7.

The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?

Nguyen THT, Guedj J, Uprichard SL, Kohli A, Kottilil S, Perelson AS.

Sci Rep. 2017 Aug 31;7(1):10233. doi: 10.1038/s41598-017-09776-z.

8.

Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies.

Best K, Guedj J, Madelain V, de Lamballerie X, Lim SY, Osuna CE, Whitney JB, Perelson AS.

Proc Natl Acad Sci U S A. 2017 Aug 15;114(33):8847-8852. doi: 10.1073/pnas.1704011114. Epub 2017 Aug 1.

9.

Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer.

Desmée S, Mentré F, Veyrat-Follet C, Sébastien B, Guedj J.

BMC Med Res Methodol. 2017 Jul 17;17(1):105. doi: 10.1186/s12874-017-0382-9.

10.

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

Cento V, Nguyen THT, Di Carlo D, Biliotti E, Gianserra L, Lenci I, Di Paolo D, Calvaruso V, Teti E, Cerrone M, Romagnoli D, Melis M, Danieli E, Menzaghi B, Polilli E, Siciliano M, Nicolini LA, Di Biagio A, Magni CF, Bolis M, Antonucci FP, Di Maio VC, Alfieri R, Sarmati L, Casalino P, Bernardini S, Micheli V, Rizzardini G, Parruti G, Quirino T, Puoti M, Babudieri S, D'Arminio Monforte A, Andreoni M, Craxì A, Angelico M, Pasquazzi C, Taliani G, Guedj J, Perno CF, Ceccherini-Silberstein F.

PLoS One. 2017 May 18;12(5):e0177352. doi: 10.1371/journal.pone.0177352. eCollection 2017.

11.

Estimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals.

Ragonnet R, Deuffic-Burban S, Boesecke C, Guiguet M, Lacombe K, Guedj J, Rockstroh JK, Yazdanpanah Y.

Open Forum Infect Dis. 2017 Jan 31;4(1):ofw235. doi: 10.1093/ofid/ofw235. eCollection 2017 Winter.

12.

Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea.

Vernet MA, Reynard S, Fizet A, Schaeffer J, Pannetier D, Guedj J, Rives M, Georges N, Garcia-Bonnet N, Sylla AI, Grovogui P, Kerherve JY, Savio C, Savio-Coste S, de Séverac ML, Zloczewski P, Linares S, Harouna S, Abdoul BM, Petitjean F, Samake N, Shepherd S, Kinda M, Koundouno FR, Joxe L, Mateo M, Lecine P, Page A, Tchamdja TM, Schoenhals M, Barbe S, Simon B, Tran-Minh T, Longuet C, L'Hériteau F, Baize S.

JCI Insight. 2017 Mar 23;2(6):e88864. doi: 10.1172/jci.insight.88864.

13.

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Nguyen TH, Guedj J, Anglaret X, Laouénan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentré F; JIKI study group.

PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.

14.

Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study.

Sissoko D, Duraffour S, Kerber R, Kolie JS, Beavogui AH, Camara AM, Colin G, Rieger T, Oestereich L, Pályi B, Wurr S, Guedj J, Nguyen THT, Eggo RM, Watson CH, Edmunds WJ, Bore JA, Koundouno FR, Cabeza-Cabrerizo M, Carter LL, Kafetzopoulou LE, Kuisma E, Michel J, Patrono LV, Rickett NY, Singethan K, Rudolf M, Lander A, Pallasch E, Bockholt S, Rodríguez E, Di Caro A, Wölfel R, Gabriel M, Gurry C, Formenty P, Keïta S, Malvy D, Carroll MW, Anglaret X, Günther S.

Lancet Glob Health. 2017 Jan;5(1):e80-e88. doi: 10.1016/S2214-109X(16)30243-1.

15.

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.

Madelain V, Guedj J, Mentré F, Nguyen TH, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01305-16. doi: 10.1128/AAC.01305-16. Print 2017 Jan. Erratum in: Antimicrob Agents Chemother. 2017 Dec 21;62(1):.

16.

Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies.

Petit C, Samson A, Morita S, Ursino M, Guedj J, Jullien V, Comets E, Zohar S.

Stat Methods Med Res. 2018 Jun;27(6):1860-1877. doi: 10.1177/0962280216671348. Epub 2016 Oct 5.

17.

Reply to: Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV - some considerations.

Canini L, Guedj J, Perelson AS.

Antivir Ther. 2016;21(7):648-649. doi: 10.3851/IMP3045. Epub 2016 Apr 1. No abstract available.

PMID:
27550924
18.

Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.

Desmée S, Mentré F, Veyrat-Follet C, Sébastien B, Guedj J.

Biometrics. 2017 Mar;73(1):305-312. doi: 10.1111/biom.12537. Epub 2016 May 5.

19.

Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection.

Banerjee S, Guedj J, Ribeiro RM, Moses M, Perelson AS.

J R Soc Interface. 2016 Apr;13(117). pii: 20160130. doi: 10.1098/rsif.2016.0130. Epub 2016 Apr 13.

20.

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Apr 5;13(4):e1002009. doi: 10.1371/journal.pmed.1002009. eCollection 2016 Apr.

21.

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley Harouna, Kighoma PM, Koundouno FR, Réné Lolamou, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar. Erratum in: PLoS Med. 2016 Jun;13(6):e1002066. PLoS Med. 2016 Apr;13(4):e1002009. Dortenzio, Eric [corrected to D’Ortenzio, Eric].

22.

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.

Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, Mentré F.

Clin Pharmacokinet. 2016 Aug;55(8):907-23. doi: 10.1007/s40262-015-0364-1. Review.

23.

Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults.

Petit C, Jullien V, Samson A, Guedj J, Kiechel JR, Zohar S, Comets E.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1481-91. doi: 10.1128/AAC.01125-15.

24.

Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).

Andrade A, Guedj J, Rosenkranz SL, Lu D, Mellors J, Kuritzkes DR, Perelson AS, Ribeiro RM; ACTG A5249s protocol team.

AIDS. 2015 Nov 28;29(18):2419-26. doi: 10.1097/QAD.0000000000000843.

25.

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.

Canini L, Guedj J, Chatterjee A, Lemenuel-Diot A, Smith PF, Perelson AS.

Antivir Ther. 2016;21(4):297-306. doi: 10.3851/IMP3006. Epub 2015 Nov 10.

26.

Ebola virus dynamics in mice treated with favipiravir.

Madelain V, Oestereich L, Graw F, Nguyen TH, de Lamballerie X, Mentré F, Günther S, Guedj J.

Antiviral Res. 2015 Nov;123:70-7. doi: 10.1016/j.antiviral.2015.08.015. Epub 2015 Sep 2.

27.

HCV Kinetic Models and Their Implications in Drug Development.

Nguyen T, Guedj J.

CPT Pharmacometrics Syst Pharmacol. 2015 Apr;4(4):231-42. doi: 10.1002/psp4.28. Epub 2015 Apr 17. Review.

28.

A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy.

Laouénan C, Guedj J, Peytavin G, Nguyen TT, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Marcellin P, Mentré F.

CPT Pharmacometrics Syst Pharmacol. 2015 Jan;4(1):e00008. doi: 10.1002/psp4.8. Epub 2014 Dec 30.

29.

Modelling hepatitis C therapy--predicting effects of treatment.

Perelson AS, Guedj J.

Nat Rev Gastroenterol Hepatol. 2015 Aug;12(8):437-45. doi: 10.1038/nrgastro.2015.97. Epub 2015 Jun 30. Review.

30.
31.

Favipiravir for children with Ebola.

Bouazza N, Treluyer JM, Foissac F, Mentré F, Taburet AM, Guedj J, Anglaret X, de Lamballerie X, Keïta S, Malvy D, Frange P.

Lancet. 2015 Feb 14;385(9968):603-604. doi: 10.1016/S0140-6736(15)60232-X. No abstract available.

PMID:
25706078
32.

Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study.

K-Kutala B, Bedossa P, Guedj J, Asselah T, Martinot-Peignoux M, Duval X, Marcellin P.

Dig Liver Dis. 2015 Apr;47(4):296-302. doi: 10.1016/j.dld.2014.12.010. Epub 2014 Dec 25.

PMID:
25596930
33.

Dose regimen of favipiravir for Ebola virus disease.

Mentré F, Taburet AM, Guedj J, Anglaret X, Keïta S, de Lamballerie X, Malvy D.

Lancet Infect Dis. 2015 Feb;15(2):150-1. doi: 10.1016/S1473-3099(14)71047-3. Epub 2014 Nov 28. No abstract available.

PMID:
25435054
34.

Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease.

Kutala BK, Guedj J, Asselah T, Boyer N, Mouri F, Martinot-Peignoux M, Valla D, Marcellin P, Duval X.

Antimicrob Agents Chemother. 2015 Feb;59(2):803-10. doi: 10.1128/AAC.04027-14. Epub 2014 Nov 17.

35.

Can we use viral kinetic models to individualize treatment?

Guedj J, Nguyen TH.

Liver Int. 2015 Feb;35(2):297-8. doi: 10.1111/liv.12736. No abstract available.

PMID:
25394573
36.

Reply: To PMID 25098971.

Guedj J, Canini L, Cotler S, Dahari H.

Hepatology. 2015 Jun;61(6):2118-9. doi: 10.1002/hep.27594. Epub 2015 Apr 18. No abstract available.

37.

A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.

Canini L, Chatterjee A, Guedj J, Lemenuel-Diot A, Brennan B, Smith PF, Perelson AS.

Antivir Ther. 2015;20(5):469-77. doi: 10.3851/IMP2879. Epub 2014 Oct 16.

38.

Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excreted.

Nguyen TT, Guedj J, Chachaty E, de Gunzburg J, Andremont A, Mentré F.

PLoS Comput Biol. 2014 Sep 11;10(9):e1003840. doi: 10.1371/journal.pcbi.1003840. eCollection 2014 Sep.

39.

A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.

Nguyen TH, Mentré F, Levi M, Yu J, Guedj J.

Clin Pharmacol Ther. 2014 Nov;96(5):599-608. doi: 10.1038/clpt.2014.173. Epub 2014 Aug 28.

40.

Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.

Sherman KE, Guedj J, Shata MT, Blackard JT, Rouster SD, Castro M, Feinberg J, Sterling RK, Goodman Z, Aronow BJ, Perelson AS.

Sci Transl Med. 2014 Jul 23;6(246):246ra98. doi: 10.1126/scitranslmed.3008195.

41.

Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, Dahari H.

Hepatology. 2014 Dec;60(6):1902-10. doi: 10.1002/hep.27357. Epub 2014 Oct 27.

42.

Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.

Laouénan C, Marcellin P, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Peytavin G, Mentré F, Guedj J.

Antimicrob Agents Chemother. 2014 Sep;58(9):5332-41. doi: 10.1128/AAC.02611-14. Epub 2014 Jun 30.

43.

Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.

Guedj J, Pang PS, Denning J, Rodriguez-Torres M, Lawitz E, Symonds W, Perelson AS.

Antivir Ther. 2014;19(2):211-20. doi: 10.3851/IMP2733. Epub 2014 Jan 24.

PMID:
24464551
44.

Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling.

Rong L, Guedj J, Dahari H, Perelson AS.

Antivir Ther. 2014;19(5):469-77. doi: 10.3851/IMP2725. Epub 2014 Jan 16.

45.

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.

Guedj J, Yu J, Levi M, Li B, Kern S, Naoumov NV, Perelson AS.

Hepatology. 2014 May;59(5):1706-14. doi: 10.1002/hep.26989. Epub 2014 Apr 1.

PMID:
24375768
46.

The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate.

Guedj J, Dahari H, Uprichard SL, Perelson AS.

Expert Rev Gastroenterol Hepatol. 2013 Jul;7(5):397-9. doi: 10.1586/17474124.2013.811050. No abstract available.

47.

Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.

Nguyen TH, Guedj J, Yu J, Levi M, Mentré F.

CPT Pharmacometrics Syst Pharmacol. 2013 Jul 17;2:e56. doi: 10.1038/psp.2013.31.

48.

NIMROD: a program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations.

Prague M, Commenges D, Guedj J, Drylewicz J, Thiébaut R.

Comput Methods Programs Biomed. 2013 Aug;111(2):447-58. doi: 10.1016/j.cmpb.2013.04.014. Epub 2013 Jun 10. Erratum in: Comput Methods Programs Biomed. 2014 Mar;113(3):927.

PMID:
23764196
49.

Umbilical artery Doppler assessment: a clear disparity in ultrasound practice in a national survey.

Cohen J, Guedj J, Fries N.

Acta Obstet Gynecol Scand. 2013 Sep;92(9):1115-6. doi: 10.1111/aogs.12167. Epub 2013 Jun 5. No abstract available.

PMID:
23663161

Supplemental Content

Support Center